DailyIQ
|
Sector:HealthcareAll sectors
Last updatedjust now

TECH·Bio-Techne Corporation

$72.34
-0.05 (-0.07%)
Overnight$72.27-0.07 (-0.10%)
High
$72.50
Open
$72.35
Market Cap
11.31B
52W High
$72.62
Low
$72.28
P. Close
$72.34
P/E
104.27
52W Low
$43.20
Fwd P/E
31.22
DailyIQ Est.
-
Inst. Ownership
63.3%
Short Interest
5.93%
Technical Score (1D)
86
BUY
News Sentiment
-
NO DATA
No summary available yet.
Earnings Summary
Bio‑Techne Corporation supplies life‑science reagents and diagnostic tools, operating through Protein Sciences and Diagnostics & Spatial Biology segments that serve research, diagnostics, and bioprocessing markets. The company’s products underpin cell and gene therapy development and regulated diagnostics, positioning it within the expanding biotechnology sector. In the last two quarters (Q2‑Q3 2025) EPS rose from $0.53 to $0.42, a slight decline, while revenue fell from $316.96 M to $286.56 M, reflecting a 9.5% drop; the company beat estimates in Q4 2024 and Q1 2025 but missed in Q3 2025, indicating a mixed recent performance. Historically, Bio‑Techne has shown steady YoY revenue growth, with EPS generally beating consensus in the first three quarters of 2025, though Q3’s miss suggests volatility in profitability. The company’s Q4 2024 earnings surpassed revenue forecasts, yet a 21‑hour downgrade by Wells Fargo signals a shift in analyst sentiment, raising uncertainty about valuation sustainability. Investors should watch the upcoming Q1 2027 guidance for revenue confirmation and any updates on the product pipeline, as well as monitor analyst rating changes and market volatility that could influence the stock’s valuation premium. The focus will be on whether the revenue upside is repeatable and how the company navigates the broader life‑sciences sector sentiment.

EPS

EstBeatMiss
$0.40$0.44$0.49$0.54$0.58Q1'25Q2'25Q3'25Q2'26Q3'26Q1'27
QtrEstActual+/−
Q1'27$0.52 - -
Q3'26$0.53$0.53-0.8%
Q2'26$0.54$0.46-14.5%
Q3'25$0.42$0.42-0.4%
Q2'25$0.50$0.53+5.8%
Q1'25$0.51$0.56+10.4%

Revenue

EstBeatMiss
$282M$292M$302M$312M$322MQ1'25Q2'25Q3'25Q2'26Q3'26Q1'27
QtrEstActual+/−
Q1'27$298M - -
Q3'26$316M$311M-1.5%
Q2'26$317M$296M-6.5%
Q3'25 - $287M -
Q2'25 - $317M -
Q1'25 - $316M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TECH Stock Snapshot

TECH is currently trading at $72.27, giving Bio-Techne Corporation a market cap of 11.31B and a P/E ratio of 104.3. Today's range spans $72.28–$72.50, with shares opening at $72.35 and moving down $0.05 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY).

Over the past year TECH has traded between $43.20 and $72.62 - the current price is +67.3% off the 52-week low and -0.5% from the high.

Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and TECH (11.31B market cap) with a BUY read (86/100) and neutral sentiment (-/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 104.3. Price: $72.27 (near 52-week highs in $43.20–$72.62). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.

The combination of a BUY signal (86/100) and neutral news sentiment (-/100) puts TECH on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 11.31B in Healthcare market cap without immediately moving the stock. At $72.27 (near 52-week highs in the $43.20–$72.62 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles